Seo Hwi Won, Suh Jae Hyun, So Seung-Ho, Kyung Jong-Soo, Kim Yong-Soon, Han Chang-Kyun
Laboratory of Fundamental Research, Korea Ginseng Corporation, Yuseong-gu, Daejeon, Republic of Korea.
Korea Occupational Safety Health Research Institute, Yuseong-gu, Daejeon, Republic of Korea.
J Ginseng Res. 2017 Oct;41(4):595-601. doi: 10.1016/j.jgr.2017.01.009. Epub 2017 Jan 19.
Red ginseng oil (RGO) is produced by supercritical CO extraction of secondary products derived from Korean Red Ginseng extract. As the use of RGO has increased, product safety concerns have become more important.
In the present study, the subacute oral toxicity and bacterial reverse mutagenicity of RGO were evaluated. Sprague-Dawley rats were orally administered with RGO for 28 d by gavage. Daily RGO dose concentrations were 0 mg/kg body weight (bw), 500 mg/kg bw, 1,000 mg/kg bw, or 2,000 mg/kg bw per day. Bacterial reverse mutation tests included five bacterial strains ( WP2 and TA98, TA100, TA1535, and TA1537), which were used in the presence or absence of metabolic activation. The plated incorporation method for mutation test was used with RGO concentrations ranging from 312.5 μg to 5,000 μg per plate.
The subacute oral toxicity test results did not reveal any marked changes in clinical characteristics. There were no toxicological changes related to RGO administration in hematological and serum biochemical characteristics in either control or treatment animals. Furthermore, no gross or histopathological changes related to RGO treatment were observed. The bacterial reverse mutation test results did not reveal, at any RGO concentration level and in all bacterial strains, any increase in the number of revertant colonies in the RGO treatment group compared to that in the negative control group.
The no-observed-adverse-effect level of RGO is greater than 2,000 mg/kg bw and RGO did not induce genotoxicity related to bacterial reverse mutations.
红参油(RGO)是通过超临界CO₂萃取韩国红参提取物的次级产物而制得。随着RGO使用量的增加,产品安全性问题变得愈发重要。
在本研究中,对RGO的亚急性经口毒性和细菌回复突变性进行了评估。将RGO通过灌胃法给予Sprague-Dawley大鼠28天。每日RGO剂量浓度分别为0毫克/千克体重(bw)、500毫克/千克bw、1000毫克/千克bw或2000毫克/千克bw。细菌回复突变试验包括五种细菌菌株(WP2和TA98、TA100、TA1535以及TA1537),在有或无代谢活化的情况下使用。突变试验采用平板掺入法,RGO浓度范围为每平板312.5微克至5000微克。
亚急性经口毒性试验结果未显示临床特征有任何明显变化。在对照组或处理组动物中,血液学和血清生化特征方面均未出现与RGO给药相关的毒理学变化。此外,未观察到与RGO处理相关的大体或组织病理学变化。细菌回复突变试验结果表明,在任何RGO浓度水平和所有细菌菌株中,RGO处理组的回复菌落数与阴性对照组相比均未增加。
RGO的未观察到有害作用水平大于2000毫克/千克bw,且RGO未诱导与细菌回复突变相关的遗传毒性。